Search Result

Pathways Recommended:	Stem Cell/Wnt

Results for "

Wnt proteins

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HSP (1) Wnt (50) Akt (2) AMPK (2) Amyloid-β (1) Antibiotic (2) Apoptosis (10) Arf Family GTPase (1) Autophagy (9) Bacterial (2) Bcl-2 Family (4) c-Myc (4) Carboxylesterase (CES) (1) Casein Kinase (2) CDK (7) Claudin (1) DNA Methyltransferase (1) Endogenous Metabolite (1) GSK-3 (8) Histone Demethylase (1) HIV (1) IKK (2) Interleukin Related (2) JNK (2) MAP4K (1) MDM-2/p53 (1) Natriuretic Peptide Receptor (NPR) (1) NF-κB (4) Organoid (7) p38 MAPK (2) Parasite (2) PARP (2) Porcupine (4) PROTACs (1) Reference Standards (8) Ser/Thr Kinase (1) sFRP-1 (4) Survivin (1) TGF-beta/Smad (2) Transthyretin (TTR) (1) α-synuclein (1) β-catenin (29)
By Research Areas:	Cancer (55) Cardiovascular Disease (5) Endocrinology (1) Infection (1) Inflammation/Immunology (9) Metabolic Disease (7) Neurological Disease (7)

By Targets:

HSP (1)

Wnt (50)

Akt (2)

AMPK (2)

Amyloid-β (1)

Antibiotic (2)

Apoptosis (10)

Arf Family GTPase (1)

Autophagy (9)

Bacterial (2)

Bcl-2 Family (4)

c-Myc (4)

Carboxylesterase (CES) (1)

Casein Kinase (2)

CDK (7)

Claudin (1)

DNA Methyltransferase (1)

Endogenous Metabolite (1)

GSK-3 (8)

Histone Demethylase (1)

HIV (1)

IKK (2)

Interleukin Related (2)

JNK (2)

MAP4K (1)

MDM-2/p53 (1)

Natriuretic Peptide Receptor (NPR) (1)

NF-κB (4)

Organoid (7)

p38 MAPK (2)

Parasite (2)

PARP (2)

Porcupine (4)

PROTACs (1)

Reference Standards (8)

Ser/Thr Kinase (1)

sFRP-1 (4)

Survivin (1)

TGF-beta/Smad (2)

Transthyretin (TTR) (1)

α-synuclein (1)

β-catenin (29)

By Research Areas:

Cancer (55)

Cardiovascular Disease (5)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (9)

Metabolic Disease (7)

Neurological Disease (7)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Wnt Slit Proteins Synaptic Vesicle Proteins HSP YTHDF

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10182

Laduviglusib Maximum Cited Publications 295 Publications Verification CHIR-99021; CT99021	Organoid GSK-3 Wnt β-catenin Autophagy	Metabolic Disease Cancer
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent *Wnt/β-catenin* signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .

HY-10182B

Laduviglusib trihydrochloride Maximum Cited Publications 295 Publications Verification CHIR-99021 trihydrochloride; CT99021 trihydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent *Wnt/β-catenin* signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy .

HY-17439

Salinomycin sodium salt 45+ Cited Publications Salinomycin sodium; Sodium salinomycin	Wnt β-catenin Bacterial Autophagy Apoptosis Antibiotic Parasite	Cancer
Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of *Wnt/β-catenin* signaling. Salinomycin sodium salt acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt shows selective activity against human cancer stem cells .

HY-10182A

Laduviglusib monohydrochloride Maximum Cited Publications 295 Publications Verification CHIR-99021 monohydrochloride; CT99021 monohydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent *Wnt/β-catenin* signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy .

HY-124745

KY-05009 1 Publications Verification	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of *Wnt* target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .

HY-147245

Basroparib STP1002	PARP	Cancer
Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC₅₀ of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC₅₀ of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks *Wnt/β-catenin* signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .

HY-113283

Homogentisic acid	Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin	Neurological Disease Metabolic Disease Cancer
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ_1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the *Wnt/β-catenin* pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .

HY-N0559

Kirenol 1 Publications Verification	Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and *Wnt/β-catenin* pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .

HY-122816

HLY78 10+ Cited Publications	Wnt β-catenin Apoptosis	Cardiovascular Disease Neurological Disease Cancer
HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the *Wnt/β-catenin* signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research .

HY-10858

WAY 316606 4 Publications Verification	sFRP-1 Wnt	Cancer
WAY 316606 is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein *Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC₅₀* of 0.5 μM .

HY-12762

QS11 2 Publications Verification	β-catenin Wnt Arf Family GTPase	Cancer
QS11 is an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC₅₀ of 1.5 μM. QS11 activates *Wnt/β-catenin* signaling through an effect on protein trafficking. QS11 inhibits migration of ARFGAP overexpressing breast cancer cells .

HY-145669

DIF-3 5+ Cited Publications	Wnt CDK GSK-3	Infection Cancer
DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo .

HY-P99667

Ipafricept 4 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-10182R

Laduviglusib (Standard) CHIR-99021 (Standard); CT99021 (Standard)	Organoid GSK-3 Autophagy Wnt β-catenin Reference Standards	Cancer
Laduviglusib (Standard) is the analytical standard of Laduviglusib. Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent *Wnt/β-catenin* signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .

HY-D1474

WNT7A-IN-1 sodium	Wnt	Cancer
WNT7A-IN-1 sodium (1365-0109), a *WNT7A* inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 sodium significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin . WNT7A-IN-1 sodium (compound F) is also a photographic sensitizer in the green spectral region .

HY-100536

IWP-3	Wnt	Cancer
IWP-3 is an potent inhibitor of *Wnt* production with an IC₅₀ of 40 nM. IWP-3 inhibits Porcupine (Porcn) function thereby blocking palmitoylation of Wnt proteins. IWP-3 inhibits CK1γ3 and CK1ε only moderately and does not inhibit CK1α .

HY-100408

GNF-6231	Wnt Porcupine	Cardiovascular Disease Cancer
GNF-6231 is a porcupine (IC₅₀= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction .

HY-117163

FzM1.8 1 Publications Verification	Wnt β-catenin	Cancer
FzM1.8, derives from FzM1, is an allosteric agonist of FZD4 with pEC₅₀ of 6.4. FzM1.8 binds to FZD4 and activates the *WNT/β-catenin* pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K .

HY-129079A

TFMB-(S)-2-HG 2 Publications Verification	DNA Methyltransferase Wnt β-catenin	Endocrinology Cancer
TFMB-(S)-2-HG is a potent TET2 inhibitor. TFMB-(S)-2-HG also inhibits the EglN prolyl hydroxylases. TFMB-(S)-2-HG downregulates *Wnt3a, β-catenin* (intranuclear) protein expression. TFMB-(S)-2-HG inhibits osteogenic differentiation of cells. TFMB-(S)-2-HG has the potential for the research of acute myeloid leukemia (AML) .

HY-170411

WNT7A-IN-1	Wnt	Cancer
WNT7A-IN-1 (1365-0109), a *WNT7A* inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin. WNT7A-IN-1 (compound F) is also a photographic sensitizer in the green spectral region .

HY-100853

IWP-O1	Porcupine Wnt	Cancer
IWP-O1 is a highly potent Porcupine (Porcn) inhibitor, with an EC₅₀ of 80 pM in L-Wnt-STF cells. IWP-O1 prevents the secretion of *Wnt* proteins. IWP-O1 suppresses the phosphorylation of Dvl2/3 and LRP6 in HeLa cells .

HY-117233

UU-T02 1 Publications Verification	β-catenin Wnt	Metabolic Disease Cancer
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a K_i of 1.36 μM . UU-T02 inhibits canonical *Wnt* signaling and the growth of colorectal cancer cells .

HY-112799

DK419	Wnt β-catenin c-Myc CDK Survivin	Cancer
DK419 is a potent and orally active *Wnt/β-catenin* signaling inhibitor, with an IC₅₀ of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .

HY-102067

3289-8625	Wnt	Cancer
3289-8625 is an inhibitor of the PDZ domain of Dishevelled (Dvl) protein (K_d=10.6 μM) and has an inhibitory effect on *Wnt* signaling. In addition, 3289-8625 can slow the growth of prostate cancer PC-3 cells (IC₅₀=12.5 μM). 3289-8625 can be used in the study of embryonic development and cancer .

HY-W100287

Murrayafoline A	NF-κB p38 MAPK Interleukin Related IKK JNK β-catenin Wnt	Neurological Disease Inflammation/Immunology Cancer
Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the *Wnt/β-catenin* pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer .

HY-10860

WAY-362692	sFRP-1 Wnt β-catenin	Metabolic Disease
WAY-362692 is a secreted frizzled-related protein (sFRP-1) inhibitor (IC₅₀ of 0.02 μM), targeting the netrin domain of sFRP-1. WAY-362692 can competitively inhibit the interaction between sFRP-1 and *Wnt* proteins, and activate the *Wnt/β-catenin* signaling pathway (EC₅₀ = 0.03 μM). WAY-362692 can activate osteoblasts and promote bone remodeling. WAY-362692 can be used for the research of metabolic disease, such as osteoporosis .

HY-10858A

WAY 316606 hydrochloride 4 Publications Verification	sFRP-1 Wnt	Cancer
WAY 316606 hydrochloride is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein *Wnt. The affinity of WAY-316606 for sFRP-1* is determined using the FP binding assay with IC₅₀ of 0.5 μM .

HY-117002

SRI 37892 1 Publications Verification	Wnt	Cancer
SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC₅₀=2μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents .

HY-112591

NSC260594 XMH95	Apoptosis HIV Wnt Bcl-2 Family	Cancer
NSC260594 induces Apoptosis. NSC260594 binds the shallow groove of the Mcl-1 protein, and inhibits Mcl-1 expression through down-regulation of *Wnt* signaling proteins. NSC260594 can also recognize G9-G10-A11-G12 RNA tetraloop of HIV and prevent the binding of the Gag protein within the 5’-UTR. NSC260594 inhibits tumor growth, and can be used for research of Triple-negative breast cancers (TNBCs) .

HY-168593

PROTAC KDM3 degrader-1	β-catenin PROTACs Wnt Histone Demethylase	Cancer
PROTAC KDM3 degrader-1 (Compound 4) is a CRBN-recruiting PROTAC designed based on the IOX1 (HY-12304) scaffold. PROTAC KDM3 degrader-1 selectively degrades the KDM3A and KDM3B proteins, thereby inhibiting the *Wnt/β-catenin* signaling pathway. PROTAC KDM3 degrader-1 significantly suppresses the self-renewal capacity of colorectal cancer stem cells and inhibits the growth of colorectal cancer tumors. PROTAC KDM3 degrader-1 is suitable for research on colorectal cancer (Target protein ligand (Pink): HY-12304; linker (Black): HY-22335; Conjugate of E3 ligase ligand and linker: HY-112599; E3 ligase (Blue): HY-41547) .

HY-E70290

N-Acetylgalactosaminyltransferase 1 GALNT1	Endogenous Metabolite β-catenin Wnt	Cancer
N-Acetylgalactosaminyltransferase 1 (GALNT1) is a glycosyltransferase that initiates mucin-type O-glycosylation by transferring α-GalNAc from UDP-GalNAc to serine (Ser) or threonine (Thr) residues in proteins. Overexpression of N-Acetylgalactosaminyltransferase 1 in gastric cancer can promote abnormal O-glycosylation of CD44, thereby activating the Wnt/β-catenin signaling pathway and regulating the malignant behavior of gastric cancer cells. Additionally, N-Acetylgalactosaminyltransferase 1 plays a crucial role in cancer growth and metastasis by modifying the O-glycosylation of various glycoproteins, such as mucin (MUC1), osteopontin (OPN), matrix metalloproteinase-14 (MMP14), and integrin α3 .

HY-17439R

Salinomycin sodium salt (Standard) Salinomycin sodium (Standard); Sodium salinomycin (Standard)	Reference Standards Wnt β-catenin Bacterial Autophagy Apoptosis Antibiotic Parasite	Cancer
Salinomycin (sodium salt) (Standard) is the analytical standard of Salinomycin (sodium salt). This product is intended for research and analytical applications. Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt (Salinomycin sodium) acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt (Salinomycin sodium) shows selective activity against human cancer stem cells .

HY-P10164

Pen-N3	Wnt	Cancer
Pen-N3 is a PDZ peptide. Pen-N3 inhibits *Wnt/b-catenin* signaling by recognizing dishevelled protein .

HY-115543

β-catenin-IN-37	Wnt β-catenin	Cancer
β-catenin-IN-37 is a selective *β-Catenin/T-cell factor protein-protein* interaction** (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC₅₀ values of 20 μM and 31 μM, respectively .

HY-10182C

Laduviglusib dihydrochloride CHIR-99021 dihydrochloride; CT99021 dihydrochloride	GSK-3 β-catenin Wnt Autophagy Organoid	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Laduviglusib dihydrochloride (CHIR-99021 dihydrochloride; CT99021 dihydrochloride) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib dihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib dihydrochloride is also a potent *Wnt/β-catenin* signaling pathway activator. Laduviglusib dihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib dihydrochloride induces autophagy .

HY-148918

E722-2648	β-catenin Wnt Bcl-2 Family	Inflammation/Immunology Cancer
E722-2648 is an inhibitor targeting the BCL9 and β-catenin complex with antitumor activity. E722-2648 blocks complex formation by disrupting the interaction between the two proteins, thereby inhibiting β-catenin-mediated transcriptional activity and downregulating the expression of *WNT* target genes. E722-2648 effectively inhibits tumor growth in colon cancer xenograft models and colorectal cancer mouse models. E722-2648 can be used for the research of colon cancer and colorectal cancer .

HY-168209

LBM22	Wnt CDK Apoptosis	Cancer
LBM22 is a CDC2-like kinase 2 (CLK2) inhibitor with the IC₅₀ of 3.9 nM. LBM22 has antiproliferative activity and inhibits serine/arginine-rich (SR) protein phosphorylation. LBM22 down-regulates the expression of Wnt-related proteins and anti-apoptotic proteins and can be used for study of non-small cell lung cancer .

HY-E70839

*KHS1 Recombinant Human Active Protein* Kinase**	Ser/Thr Kinase	Cancer
MAP4K5 (KHS1) belongs to the mammalian Ste20-like serine/threonine kinase family. MAP4K5 plays an important role in regulating a range of cellular responses and is involved in Wnt signaling in hematopoietic cells. KHS1 Recombinant Human Active Protein Kinase is a recombinant KHS1 protein that can be used to study KHS1-related functions .

HY-125201

Indazole 1	CDK	Inflammation/Immunology
Indazole 1 is a potent CDC2-like kinase 2 (CLK2) inhibitor (IC₅₀=12.3 nM). Indazole 1 inhibits the phosphorylation of SR proteins (e.g., SRSF1, SRSF3) and modulates alternative splicing of Wnt signaling-related genes. Indazole 1 is promising for research of osteoarthritis .

HY-19972

ML243	Wnt	Cancer
ML243 is a selective small-molecule inhibitor of breast cancer stem cells. ML243 has 32-fold greater selective inhibition in the breast CSC-like cell line HMLE_shECad than the control cell line HMLE_shGFP. ML243 may target the *Wnt* pathway at the protein level without altering RNA expression levels .

HY-148918A

E722-2648 TFA	β-catenin Wnt Bcl-2 Family	Cancer
E722-2648 TFA is an inhibitor targeting the BCL9 and β-catenin complex with antitumor activity. E722-2648 TFA blocks complex formation by disrupting the interaction between the two proteins, thereby inhibiting β-catenin-mediated transcriptional activity and downregulating the expression of *WNT* target genes. E722-2648 TFA effectively inhibits tumor growth in colon cancer xenograft models and colorectal cancer mouse models. E722-2648 TFA can be used for the research of colon cancer and colorectal cancer .

HY-10182AR

Laduviglusib monohydrochloride (Standard) CHIR-99021 monohydrochloride (Standard); CT99021 monohydrochloride (Standard)	Organoid Reference Standards GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (monohydrochloride) (Standard) is the analytical standard of Laduviglusib (monohydrochloride). This product is intended for research and analytical applications. Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy .

HY-141543

YW2065	β-catenin	Cancer
YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of wnt/β-catenin signaling inhibition and AMPK activation .

HY-E70661

*CDK14/CycY Recombinant Human Active Protein* Kinase**	CDK	Cancer
CDK14 is a member of the TAIRE subfamily. CDK14/CycY Recombinant Human Active Protein Kinase is an ortholog of CDK14. CDK14/CycY phosphorylates S1490 of LRP6 during the G2/M transition in a Wnt-independent manner .

HY-E70690

*CDK8/CycC Recombinant Human Active Protein* Kinase**	CDK	Cancer
CDK8 modulates the transcriptional output from distinct transcription factors involved in oncogenic control, including the Wnt/β-catenin pathway, Notch, p53, and transforming growth factor β. Abnormal activity ofCDK8 along with its partner protein cyclin C (CycC) is a common feature of many diseases including colorectal cancer. CDK8/CycC Recombinant Human Active Protein Kinase can be used to study the function of CDK8/CycC .

HY-169348

β-catenin-IN-8	β-catenin Wnt c-Myc	Cancer
β-catenin-IN-8 (Compound 25) is a β-catenin inhibitor. β-catenin-IN-8 inhibits β-catenin and c-Myc protein levels, and inhibits *Wnt*-target genes level (Fgf20 and Sall4). β-catenin-IN-8 has colorectal cancer anticancer activities, and has metabolic stability .

HY-164520

PMED-1	Wnt	Cancer
PMED-1 is a β-catenin inhibitor that significantly reduces β-catenin activity in hepatoblastoma cells and various HCC cells, with an IC₅₀ value ranging from 4.87 to 32 μM. PMED-1 affects *Wnt* signaling by decreasing the interaction between β-catenin and CREB binding protein, thereby inhibiting cell proliferation. PMED-1 has potential applications in cancer research .

HY-10182BR

Laduviglusib trihydrochloride (Standard) CHIR-99021 trihydrochloride (Standard); CT99021 trihydrochloride (Standard)	Organoid Reference Standards GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (trihydrochloride) (Standard) is the analytical standard of Laduviglusib (trihydrochloride). This product is intended for research and analytical applications. Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy .

HY-161826

Antitumor agent-174	Wnt β-catenin HSP CDK c-Myc	Cancer
Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity .

HY-N0559R

Kirenol (Standard)	Reference Standards Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Kirenol (Standard) is the analytical standard of Kirenol (HY-N0559). This product is intended for research and analytical applications. Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis.

Cat. No.	Product Name

HY-L017

Stem Cell Signaling Compound Library

2,723 compounds

Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.

MCE owns a unique collection of 2,723 compounds that can be used for stem cell regulatory and signaling pathway research.

HY-L020

Wnt/Hedgehog/Notch Compound Library

601 compounds

The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells. The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development.

MCE designs a unique collection of 601 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.

HY-L038

Differentiation Inducing Compound Library

2,405 compounds

Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.

MCE Differentiation Inducing Compound Library contains a unique collection of 2,405 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.

Cat. No.	Product Name	Target	Research Area